Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 18, 2023
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
[ Thu, May 18th 2023
] - WOPRAI
Pete Stavropoulos Initiated (ABOS) at Buy and Held Target at $13 on, May 18th, 2023
Pete Stavropoulos of Cantor Fitzgerald, Initiated "Acumen Pharmaceuticals, Inc." (ABOS) at Buy and Held Target at $13 on, May 18th, 2023.
Pete has made no other calls on ABOS in the last 4 months.
There are 2 other peers that have a rating on ABOS. Out of the 2 peers that are also analyzing ABOS, 0 agree with Pete's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Pete
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Tuesday, March 28th, 2023
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $13 on, Tuesday, March 28th, 2023
